Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech

Dow Jones07-07

Shares of Aligos Therapeutics surged after the company received a $25 million upfront payment as part of a licensing deal with Xiamen Amoytop Biotech.

The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year.

The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China.

Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories.

Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea.

Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter.

Write to Grace Yoon at grace.yoon@wsj.com

(END) Dow Jones Newswires

July 06, 2026 17:53 ET (21:53 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649674118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 05:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649674118","market":"us","top_or_hot":-1,"title":"Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Aligos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> surged after the company received a $25 million upfront payment as part of a licensing deal with <a href=\"https://laohu8.com/S/688278\">Xiamen Amoytop Biotech</a>. \n</p>\n<p>\n  The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year. \n</p>\n<p>\n  The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China. \n</p>\n<p>\n  Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories. \n</p>\n<p>\n  Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea. \n</p>\n<p>\n  Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 06, 2026 17:53 ET (21:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-07 05:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Aligos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> surged after the company received a $25 million upfront payment as part of a licensing deal with <a href=\"https://laohu8.com/S/688278\">Xiamen Amoytop Biotech</a>. \n</p>\n<p>\n  The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year. \n</p>\n<p>\n  The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China. \n</p>\n<p>\n  Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories. \n</p>\n<p>\n  Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea. \n</p>\n<p>\n  Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 06, 2026 17:53 ET (21:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2649674118","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649674118","pubTimestamp":1783374780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Aligos Therapeutics surged after the company received a $25 million upfront payment as part of a licensing deal with Xiamen Amoytop Biotech.The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year.The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China.Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories.Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea.Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter.Write to Grace Yoon at grace.yoon@","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688278":"特宝生物","BK4581":"高盛持仓","ALGS":"Aligos Therapeutics, Inc.","BK0239":"医药制造","XBI":"SPDR S&P Biotech ETF","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"厦门淘拓生物科技支付2500万美元后，Aligos Therapeutics股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688278":0.9,"ALGS":1.5,"XBI":1.5},"content_text":"Shares of Aligos Therapeutics surged after the company received a $25 million upfront payment as part of a licensing deal with Xiamen Amoytop Biotech. \n\n\n  The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year. \n\n\n  The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China. \n\n\n  Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories. \n\n\n  Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea. \n\n\n  Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter. \n\n\n \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 06, 2026 17:53 ET (21:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649674118","isCrawlerRequest":true}